Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

How Does AICAR Become ZMP Inside Cells?

Conceptual illustration of a riboside passing through a membrane transporter and acquiring a phosphate inside the cell.

AICAR becomes ZMP after cellular uptake and phosphorylation by adenosine kinase (ADK). AICAR here means acadesine, or AICA riboside: ADK transfers a phosphate from ATP onto its ribose 5′ hydroxyl, producing the monophosphate ZMP, also called AICA ribotide. The conversion has been demonstrated in isolated rat hepatocytes[1]. Uptake through equilibrative nucleoside transporter 1 (ENT1) is an upstream requirement in primary mouse hepatocytes[2]. The riboside is therefore a precursor in this AMPK-activation route, rather than the direct AMP-mimicking ligand. ZMP binds the regulatory γ-subunit CBS domains of AMPK and can also inhibit AMP deaminase, although the latter interaction was measured with a millimolar inhibition constant in purified-enzyme experiments[3][4].

AICAR and ZMP Differ by One 5′ Phosphate

AICAR and ZMP share the same base and ribose; ZMP additionally carries a 5′ phosphate. AICAR normally means the riboside (the nucleoside), while ZMP means the ribotide (the 5′-monophosphate)[5]. The base is 5-aminoimidazole-4-carboxamide, the ribose is attached at N1, and the only structural difference between the pair is the phosphate ester at the 5′ position of that ribose. Identity records for the ribotide list CAS 3031-94-5, PubChem 65110, ChEBI 18406 and KEGG C04677, with the systematic name [(2R,3S,4R,5R)-5-(5-amino-4-carbamoyl-1H-imidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate[5].

The naming can otherwise obscure which molecule an experiment measures. Some biochemical literature calls the ribonucleotide AICAR, whereas cellular pharmacology often uses AICAR for the added riboside[5]. In this article, AICAR always means the riboside and ZMP the monophosphate. The concentration of riboside added to a culture is not a measurement of the intracellular ZMP pool. That pool can receive material through phosphorylation of the supplied riboside and through de novo purine synthesis[1][6].

Cell Entry Goes Through Equilibrative Nucleoside Transporters

In primary mouse hepatocytes, AICAR increased AMPK-pathway phosphorylation and suppressed stimulated hepatic glucose production. The compounds 8CPT-cAMP, 8CPT-2-methyl-O-cAMP and NBMPR interfered with those effects at least partly by impeding AICAR uptake. Metformin retained its effect under those conditions. This identifies transport as a determinant of the cellular AICAR response, rather than showing that the downstream AMPK machinery cannot respond[2].

ENT1 is the transporter implicated in that hepatocyte work. ENT2 cannot be assigned an equivalent role from these experiments; its contribution to AICAR entry remains unresolved here. If a cell produces little ZMP after exposure to the riboside, poor uptake is one possible explanation, but a low ZMP measurement alone does not identify the transport step as the cause. Phosphorylation and subsequent metabolism also affect the pool.

Adenosine Kinase Adds the 5′ Phosphate

Schematic enzyme pockets depict phosphate addition to a riboside and removal from its phosphorylated form.

Isolated rat hepatocytes take up AICA riboside and convert it to ZMP through adenosine kinase (ATP:adenosine 5′-phosphotransferase, EC 2.7.1.20), the ribotide being an intermediate of de novo purine nucleotide synthesis[1]. Adding 50 µM iodotubercidin, an adenosine kinase inhibitor, to hepatocytes that had already metabolized AICA riboside made ZMP fall immediately and AICA riboside rise again[1]. The fall in ZMP after kinase inhibition, together with the renewed rise in riboside, supports continued interconversion rather than irreversible accumulation.

The reverse reaction runs too. In crude rat liver cytosolic extracts, ZMP dephosphorylation followed hyperbolic kinetics with a Vmax of 0.65 µmol/min per g protein and an apparent Km of 5 mM, and was markedly inhibited by inorganic phosphate, an inhibitor of IMP-GMP 5′-nucleotidase[1]. The authors concluded that hepatocyte ZMP is continuously dephosphorylated, most likely by IMP-GMP 5′-nucleotidase, back to AICA riboside, which adenosine kinase then rephosphorylates — a substrate cycle between riboside and ribotide[1]. Two consequences follow: ZMP is not a one-way trap, and anything that shifts kinase or nucleotidase activity changes the steady-state ZMP level without changing how much AICAR was added.

ZMP Is an Intermediate of De Novo Purine Synthesis

Three successive abstract metabolite states represent the onward sequence from ZMP through FAICAR to IMP.

ZMP was not invented for kinase experiments; the ribotide is a normal intermediate of de novo purine biosynthesis[5]. The pathway runs from ZMP toward IMP, not from IMP toward ZMP. ZMP is converted to 5-formamido-4-imidazolecarboxamide ribonucleotide (FAICAR) and then to IMP, and both steps belong to one bifunctional enzyme, ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, EC 2.1.2.3 / IMP cyclohydrolase, EC 3.5.4.10), which carries out the last two reactions of the pathway[6]. ZMP therefore sits upstream of IMP on the biosynthetic route, not downstream of AMP.

Onward conversion can therefore affect ZMP accumulation independently of the initial ADK reaction. A CRISPR-Cas9 HeLa line lacking ATIC accumulated ZMP during purine starvation[6]. This illustrates a second route to a larger ZMP pool: impaired consumption of a biosynthetic intermediate, rather than increased entry of extracellular riboside. The pathway position explains where ZMP can go next; its AMP-mimicking activity is a separate property, supported by nucleotide-binding evidence rather than by its place in purine synthesis.

ZMP Binds the AMPK γ-Subunit CBS Domains

AMPK senses energy status through binding of AMP and ATP to CBS (cystathionine beta-synthase) domains in the regulatory γ subunit. A crystal structure of a CBS-domain pair from human AMPK γ1 was solved with the physiological activator AMP and with the pharmacological activator ZMP[3]. ZMP therefore occupies the same domain pair that binds AMP — the structural basis of the "AMP mimic" description — rather than acting through a separate site.

For AMP, occupancy of those CBS domains switches the kinase on by three routes, all of which ATP opposes: it promotes phosphorylation of Thr172 by upstream activating kinases, it inhibits dephosphorylation of Thr172 by phosphatases, and it allosterically activates the kinase that is already phosphorylated at Thr172[7]. The third mechanism has been argued to be quantitatively significant in intact cells[7]. These AMP mechanisms provide a framework for interpreting an AMP-mimicking ligand, not a measurement of ZMP equivalence. The ZMP-bound γ1 structure supports ligand recognition; it does not quantify ZMP-dependent allosteric activation or protection from dephosphorylation in intact cells.

Binding, phosphorylation and catalytic output answer different questions. An isolated CBS-domain pair establishes ligand recognition, whereas the AMP regulatory mechanisms involve both the phosphorylation state and the activity of AMPK. A cellular interpretation should therefore distinguish direct ZMP measurement from AMPK-pathway phosphorylation, rather than treating either as a substitute for the other.

ZMP Can Inhibit AMP Deaminase

ZMP was characterized as a competitive inhibitor of 5′-adenylate deaminase (AMP deaminase) with a Ki of 1.01 mM, while the riboside AICA riboside was a competitive inhibitor of adenosine deaminase with a Ki of 362 µM, both measured with purified enzymes in a spectrophotometric assay[4]. The millimolar Ki describes the purified-enzyme interaction, not a universal intracellular cutoff. It makes ZMP accumulation relevant to interpreting this possible effect, but does not establish how much AMP deaminase is inhibited in any particular cell. The riboside and ribotide also inhibited different enzymes in this assay; their effects should not be treated as interchangeable.

That range is reached in some settings and not others. At 500 µM AICA riboside, ZMP was undetectable in rabbit cardiomyocytes but reached 0.65 mM in human erythrocytes and 5 mM in rat FTO-2B hepatoma cells[8]. Those measurements demonstrate unequal ZMP accumulation, not measurements of AMP deaminase inhibition in the three cell types.

Glycolysis and PFK-1 Respond Only in Some Cell Types

The same cell-type dependence appears for glycolysis. AICA riboside inhibited glycolysis in isolated rat hepatocytes, and the effect was mediated by ZMP, the product of adenosine kinase[8]. In the same study it had no effect on glycolysis in cardiomyocytes, had a slight stimulatory effect in erythrocytes, and inhibited glycolysis by 65% at 250 µM in FTO-2B cells[8]. In cell-free extracts of FTO-2B cells, phosphofructokinase-1 (PFK-1) activity measured under physiological conditions was inhibited by about 70% at 5 mM ZMP[8].

These findings connect high ZMP accumulation with a possible direct effect on PFK-1 in the hepatoma model. They do not establish a universal threshold or make ZMP concentration alone sufficient to predict glycolysis: erythrocytes accumulated measurable ZMP yet showed slight stimulation rather than inhibition. Undetectable ZMP in cardiomyocytes likewise means below the assay’s detection capability, not proof that the nucleotide was absent.

What to Measure to Show the Conversion Happened

A p-AMPK blot alone cannot separate "AICAR was converted to ZMP" from "AMPK was phosphorylated for another reason." A useful interpretation separates metabolite formation, pathway response and conversion dependence:

  • ZMP itself, measured directly rather than inferred from phosphorylation. In cultured rat aortic smooth muscle cells, 1 mM AICAR for 30 minutes raised ZMP from 8.5 ± 0.6 to 2014.9 ± 179.4 picomoles per mg protein, with the ATP/ADP ratio falling from 2.08 ± 0.06 to 1.08 ± 0.02 over the same exposure[9].
  • AMPK-pathway phosphorylation, considered separately from metabolite abundance. As an experimental interpretation, comparing p-AMPK with an additional pathway readout such as ACC phosphorylation is more informative than assigning conversion from p-AMPK alone. ACC phosphorylation is a proposed companion readout here, not a result reported in the supplied abstracts.
  • A conversion control: an adenosine kinase inhibitor such as 5-iodotubercidin. In rat aortic rings, 1 mM AICAR for 30 minutes inhibited phenylephrine-induced contraction by about 35%, and this response was prevented by 1 µM 5-iodotubercidin and by 40 µM compound C, but not by the adenosine receptor blocker 8-sulfophenyltheophylline at 100 µM[9]. This pharmacological result supports ADK involvement in that preparation; it is not itself a ZMP measurement.

Exposure concentration, duration and cell identity belong beside the result. The smooth-muscle measurements describe one laboratory exposure, not a concentration–time curve. They do not establish the ZMP level reached with a lower concentration, a longer incubation or a different cell type.

ZMP-Dependent Does Not Always Mean AMPK-Dependent

In 3T3-L1 adipocytes, AICAR inhibited insulin-stimulated glucose uptake by a mechanism requiring conversion to ZMP but independent of AMPK. GLUT4 trafficking to the plasma membrane was impaired without changes in total GLUT4 or AKT signalling. The comparator 991 did not reproduce the effect, and sustained AMPK downregulation did not alter glucose uptake[10]. This is a cell-line finding, not a demonstration in human adipose tissue. It shows why confirming conversion and assigning the resulting effect to AMPK are separate tasks.

The evidence spans purified-enzyme assays, an isolated human AMPK γ1 domain structure, cultured or isolated cells, and ex vivo rat aortic rings. Isolated human erythrocytes are human-derived material, not a study of outcomes in people. Neither the γ1 structure nor the animal-derived preparations establishes human metabolic benefit, a physiological ZMP signalling role, or identical responses across AMPK isoforms. The cell and tissue findings above should be interpreted within those experimental settings.

Related research: What Is AICAR: Acadesine as an AMPK Activator; What Is MOTS-c: Mitochondrial-Derived Peptide; AICAR.

Research Use Only Disclaimer. This article is for laboratory research and analytical education only. It is not a validated experimental protocol or medical or veterinary advice. The materials discussed are not for administration to humans or animals.

References

  1. Substrate cycling between 5-amino-4-imidazolecarboxamide riboside and its monophosphate in isolated rat hepatocytes (Biochem Pharmacol, 1996)
  2. Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
  3. Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP (Acta Crystallogr D, 2007)
  4. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide (1986)
  5. AICA ribonucleotide (ZMP) — Wikipedia
  6. The CRISPR-Cas9 crATIC HeLa transcriptome: characterization of a cellular model of ATIC deficiency and ZMP accumulation
  7. AMPK: a cellular energy sensor primarily regulated by AMP (2014)
  8. Cell-type specificity of inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside (1995)
  9. AICAR promotes endothelium-independent vasorelaxation by activating AMPK via increased ZMP and decreased ATP/ADP ratio in aortic smooth muscle (2022)
  10. AICAR Inhibits Insulin-Stimulated Glucose Uptake in 3T3-L1 Adipocytes via an AMPK-Independent, ZMP-Dependent Mechanism (Cells 2025)